FindTrial
Sign In

Ipratropio bromuro-albuterol association vs salbutamolo in asthma and gastroesophageal reflux - ND

Ipratropio bromuro-albuterol association vs salbutamolo in asthma and gastroesophageal reflux - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005550-23-IT
Enrollment
Unknown
Registered
2008-03-12
Start date
2008-10-07
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma MedDRA version: 9.1 Level: LLT Classification code 10003553 Term: Asthma

Interventions

Trade Name: BREVA Pharmaceutical Form: Pressurised inhalation, solution INN or Proposed INN: SALBUTAMOLO CAS Number: 18559-94-9 Concentration unit: µg microgram(s) Concentration type: equal Concentrat

Sponsors

ISTITUTO GIANNINA GASLINI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 6 to 12 years old children with asthma and gastroesophageal reflux Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Other chronic disease

Design outcomes

Primary

MeasureTime frame
Main Objective: Verify if the Ipratropio bromuro-albuterol association improve PEFR (FEV1, FVC e FEV1/FVC).;Secondary Objective: To evaluate if the association of Ipratropium Bromide and Albuterol is more effective than Albuterol to improve pulmonary function tests and asthma symptoms control.;Primary end point(s): Verify if the Ipratropio bromuro-albuterol association improve PEFR (FEV1, FVC e FEV1/FVC).—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026